Pfizer Inc
PFE- Latest Trade
- trading higher50.96USD
- Change
- 0.3
- % Change
0.60%Positive
- Day Range
- 50.66 - 51.44
- 52-Week Range
- 38.82 - 61.71
As of Jun 29 2022. Values delayed up to 15 minutes
- Previous Close
- 50.66
- Open
- 50.73
- Volume
- 11,159,010.00
- 3 Month Average Trading Volume
- 515.04
- Shares Out (Mil)
- 5,610.90
- Market Cap
- 291,093.30
- Forward P/E
- 7.43
- Dividend Yield
- 3.08
Key Statistics
2.34615385 mean rating - 26 analysts
- P/E Excl. Extra Items (TTM)
- 11.70
- Price To Sales (TTM)
- 3.15
- Price To Book (Quarterly)
- 3.52
- Price To Cash Flow (Per Share TTM)
- 9.51
- Total Debt/Total Equity (Quarterly)
- 44.04
- Long Term Debt/Equity (Quarterly)
- 43.26
- Return On Investment (TTM)
- 18.43
- Return On Equity (TTM)
- 14.86
2021 (millions USD)
About Pfizer Inc
Company Information
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company offers therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator in development for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. The Company's medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness.
Address
235 E 42ND STNEW YORK, NY
10017-5703
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Albert Bourla
- Chairman of the Board, Chief Executive Officer
- David M. Denton
- Executive Vice President, Chief Financial Officer
- Angela Hwang
- Group President - Pfizer Biopharmaceuticals Group
- Lidia Fonseca
- Executive Vice President, Chief Digital and Technology Officer
- Rady A. Johnson
- Executive Vice President, Chief Compliance, Quality and Risk Officer
- Douglas M. Lankler
- Executive Vice President, General Counsel
- William R. Carapezzi
- Executive Vice President - Global Business Services and Transformation
- Aamir Malik
- Executive Vice President, Chief Business Innovation Officer
- Michael Mcdermott
- Executive Vice President, Chief Global Supply Officer
- Payal Sahni
- Executive Vice President, Chief People Experience Officer
- Sally Susman
- Executive Vice President, Chief Corporate Affairs Officer
- Mikael G. Dolsten
- Chief Scientific Officer, President - Worldwide Research, Development and Medical
- Shantanu Narayen
- Lead Independent Director
- Ronald E. Blaylock
- Independent Director
- Susan D. Desmond-Hellmann
- Independent Director
- Joseph J. Echevarria
- Independent Director
- Scott Gottlieb
- Independent Director
- Helen H. Hobbs
- Independent Director
- Susan J. Hockfield
- Independent Director
- Dan R. Littman
- Independent Director
- Suzanne Nora Johnson
- Independent Director
- James R. Quincey
- Independent Director
- James Clifton Smith
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,816.00 | 0.08%Negative |
| Copper | 694.25 | 1.57%Negative |
| Brent Crude Oil | 115.50 | 2.10%Negative |
| CBOT Soybeans | 1,672.00 | 0.50%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,813.89 | 0.20%Negative |
| Euro STOXX 50 | 3,514.32 | 0.99%Negative |
| FTSE 100 | 7,312.32 | 0.15%Negative |
| Nikkei 225 | 26,804.60 | 0.91%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes